Clinical Trial Update: A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 study of mirikizumab in moderate to severe ulcerative colitis completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Mirikizumab (mirikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Ulcerative Colitis | Phase 2 | Status: COMPLETED | Results posted: 2020-05-29